Literature DB >> 27588438

VLDL Triglyceride Kinetics in Lean, Overweight, and Obese Men and Women.

Bettina Mittendorfer1, Mihoko Yoshino1, Bruce W Patterson1, Samuel Klein1.   

Abstract

CONTEXT: High-plasma very low-density lipoprotein (VLDL) triglyceride (TG) concentration and alterations in VLDL-TG metabolism are associated with cardiometabolic disease.
OBJECTIVE: This study sought to evaluate the interrelationships among factors purported to regulate VLDL-TG metabolism in a large cohort of men and women with a wide range in body adiposity and fat distribution but without diabetes. SUBJECTS AND
DESIGN: We assessed body composition and fat distribution, plasma insulin concentration, free fatty acid availability, and basal VLDL-TG and VLDL-apoB-100 (VLDL particle number) kinetics in 233 lean, overweight, and obese men and women.
RESULTS: We found that: 1) plasma VLDL-TG concentration is determined primarily by VLDL-TG secretion rate (SR) in men and by VLDL-TG clearance rate in women; 2) there is a dissociation between VLDL-TG and VLDL-apoB-100 SRs, and VLDL-apoB-100 SR only explains ∼30% of the variance in VLDL-TG SR; 3) ∼50% of people with obesity have high plasma VLDL-TG concentration due to both an increased VLDL-TG SR and a decreased rate of VLDL-TG plasma clearance, and they have lower plasma high-density lipoprotein-cholesterol concentration and more intra-abdominal and liver fat than those with normal VLDL-TG concentration; and 4) fat-free mass, liver fat content and the rate of free fatty acid release into plasma are independent predictors (with a sex × race interaction) of VLDL-TG SR.
CONCLUSIONS: The regulation of plasma VLDL-TG concentration is complex and influenced by multiple metabolic factors. Many people with obesity have normal plasma VLDL-TG concentrations and kinetics, whereas those with high plasma VLDL-TG concentrations have increased VLDL-TG SR and other markers of cardiometabolic disease risk.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27588438      PMCID: PMC5095238          DOI: 10.1210/jc.2016-1500

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

1.  Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.

Authors:  Elisa Fabbrini; B Selma Mohammed; Faidon Magkos; Kevin M Korenblat; Bruce W Patterson; Samuel Klein
Journal:  Gastroenterology       Date:  2007-11-28       Impact factor: 22.682

2.  Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity.

Authors:  Bettina Mittendorfer; Bruce W Patterson; Samuel Klein
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-12-10       Impact factor: 4.310

3.  Young women partition fatty acids towards ketone body production rather than VLDL-TAG synthesis, compared with young men.

Authors:  Kyriakoula Marinou; Martin Adiels; Leanne Hodson; Keith N Frayn; Fredrik Karpe; Barbara A Fielding
Journal:  Br J Nutr       Date:  2011-01-21       Impact factor: 3.718

4.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

5.  Testosterone increases the muscle protein synthesis rate but does not affect very-low-density lipoprotein metabolism in obese premenopausal women.

Authors:  Xuewen Wang; Gordon I Smith; Bruce W Patterson; Dominic N Reeds; Janine Kampelman; Faidon Magkos; Bettina Mittendorfer
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-17       Impact factor: 4.310

6.  Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue.

Authors:  S B Pedersen; M Jønler; B Richelsen
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958

7.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.

Authors:  Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

8.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

9.  The case of visceral fat: argument for the defense.

Authors:  Samuel Klein
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

10.  Role of very low density lipoproteins in the energy metabolism of the rat.

Authors:  R R Wolfe; M J Durkot
Journal:  J Lipid Res       Date:  1985-02       Impact factor: 5.922

View more
  26 in total

Review 1.  Unexplained reciprocal regulation of diabetes and lipoproteins.

Authors:  Sei Higuchi; M Concepción Izquierdo; Rebecca A Haeusler
Journal:  Curr Opin Lipidol       Date:  2018-06       Impact factor: 4.776

Review 2.  Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.

Authors:  Fabiana de Faria Ghetti; Daiane Gonçalves Oliveira; Juliano Machado de Oliveira; Lincoln Eduardo Villela Vieira de Castro Ferreira; Dionéia Evangelista Cesar; Ana Paula Boroni Moreira
Journal:  Eur J Nutr       Date:  2017-09-05       Impact factor: 5.614

Review 3.  Different physiological mechanisms underlie an adverse cardiovascular disease risk profile in men and women.

Authors:  Alan Fappi; Bettina Mittendorfer
Journal:  Proc Nutr Soc       Date:  2019-07-25       Impact factor: 6.297

4.  Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity.

Authors:  Kelli A Lytle; Nikki C Bush; Jessica M Triay; Todd A Kellogg; Michael L Kendrick; James M Swain; Nicola W Gathaiya; Kazanna C Hames; Michael D Jensen
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

5.  Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Arun J Sanyal; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2019-03-07       Impact factor: 17.425

Review 6.  Intra-pancreatic fat deposition: bringing hidden fat to the fore.

Authors:  Maxim S Petrov; Roy Taylor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-08       Impact factor: 46.802

7.  QTc Interval is Associated with Atrial Fibrillation in Individuals with Metabolic Syndrome Phenotype.

Authors:  Ming-Chuan Lee; Yu-Tsang Wang; Yu-Ju Li; Ching-Yi Tsai; Su-Te Chen; Wun-Jyun Jhuang; Meng-Chi Chang; Mei-Yu Chien; Hsiang-Chun Lee
Journal:  Int J Gen Med       Date:  2022-07-15

8.  Lipoprotein Insulin Resistance Index Reflects Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Anusha Vittal; Mark Shapses; Bashar Sharma; Disha Sharma; Qian Sun; Maureen Sampson; Wilson Lee; Gil Ben Yakov; Yaron Rotman
Journal:  Hepatol Commun       Date:  2020-12-29

9.  Individualization of the infusion rate of a soybean oil-based intravenous lipid emulsion for inpatients, based on baseline triglyceride concentrations: A population pharmacokinetic approach.

Authors:  Keizo Fukushima; Kenji Omura; Satoshi Goshi; Akira Okada; Motomu Tanaka; Takae Tsujimoto; Keiji Iriyama; Nobuyuki Sugioka
Journal:  JPEN J Parenter Enteral Nutr       Date:  2021-05-12       Impact factor: 3.896

10.  Subcutaneous Adipose Tissue Metabolic Function and Insulin Sensitivity in People With Obesity.

Authors:  Han-Chow E Koh; Stephan van Vliet; Terri A Pietka; Gretchen A Meyer; Babak Razani; Richard Laforest; Robert J Gropler; Bettina Mittendorfer
Journal:  Diabetes       Date:  2021-07-15       Impact factor: 9.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.